IQV logo

IQVIA

IQV · What the business does, what can go wrong, and how options sellers approach it

What it does

IQVIA helps drugmakers, device makers and other healthcare organizations develop and sell their products. It combines three things: outsourced clinical trial services, healthcare data and analytics, and technology that supports both.

It was formed by the combination of a contract research organization and a healthcare data company, and that mix still defines it.

How it makes money

Most revenue comes from two areas.

  • Research and development services: Clients pay IQVIA to run clinical trials, from recruiting patients and sites to managing data and regulatory work. Contracts are often multi-year and billed as trials progress.
  • Technology and analytics: Clients pay for data, software and consulting that help them understand prescribing patterns, market trends and commercial performance. Much of this is subscription or recurring.

It also runs a smaller contract sales business, supplying outsourced sales teams.

Why investors own it

Investors often see it as a way to own drug development growth without betting on one drug. Its data assets are hard to replicate, and long trial contracts give some visibility into future work. Some like the mix of project-based and recurring revenue.

What can go wrong

  • Drug companies may cut research budgets, delay trials or shift work to competitors.
  • Biotech funding tends to swing with markets, which can affect new project demand.
  • Trial cancellations can reduce expected revenue.
  • Pricing pressure and competition from other research organizations are ongoing risks.
  • Data privacy rules and regulatory changes could limit how healthcare data is collected or used.
  • The company carries meaningful debt, which adds risk if conditions weaken.

What to watch

  • Backlog (contracted future work) and new business bookings
  • Cancellation trends
  • Growth in research and development services versus technology and analytics
  • Operating margins
  • Biotech funding conditions
  • Pharma industry research spending
  • Debt levels and capital return policy

Options income angle

Options on IQV are generally available across many strikes and expirations, and the more active ones tend to be reasonably liquid.

Implied volatility tends to rise ahead of quarterly earnings, when backlog and bookings updates can move the stock sharply. Shifts in biotech sentiment and healthcare policy news can also lift it.

One caution for anyone selling premium: a disappointing earnings report or guidance change can gap the share price and overwhelm the premium collected, especially for options held through an earnings date.

What the latest 10-K says

A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed February 17, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The filing in brief

IQVIA reported 2025 revenues of $16,310 million, up 5.9% from 2024, with growth in all three segments. Costs grew faster than revenue, and profit in the largest segment, Research & Development Solutions, slipped. The filing also shows a heavy debt load of $15,800 million and a reorganization into two reporting segments starting in 2026.

How the business did

  • Revenues rose to $16,310 million from $15,405 million. Technology & Analytics Solutions grew 7.6%, led by Real-World services and information and technology services. Research & Development Solutions grew 4.3%, helped by higher volumes of clinical services and by better growth in the second half of the year.
  • Margins tightened. Cost of revenues, excluding depreciation and amortization, was 66.7% of revenues versus 65.1% a year earlier. Research & Development Solutions segment profit was $1,873 million versus $1,948 million in 2024.
  • Net cash from operating activities was $2,654 million, versus $2,716 million in 2024. The company spent $1,714 million, net of cash acquired, on acquisitions and ended the year with cash of $1,980 million.
  • Interest expense was $729 million, up from $670 million because of higher debt balances. Restructuring costs were $105 million. The effective income tax rate was 15.8% versus 18.0%, helped by a shift in where profits were earned.

Risks specific to this company

  • Cancellable contracts. Most Research & Development Solutions clients can end contracts on 30 to 90 days' notice. Wind-down fees may not make up the lost revenue, and backlog (signed but unfinished work) is not guaranteed.
  • Debt and covenants. The credit agreement requires a maximum senior secured net leverage ratio and a minimum interest coverage ratio. A breach could let lenders accelerate repayment and act on pledged assets. Some variable-rate debt is not hedged.
  • Fixed-price work. Many trial contracts are fee for service or fixed-fee. If costs overrun and the company cannot win change orders for out-of-scope work, it absorbs the cost. Flawed trial data can force a repeat trial at the company's expense.
  • AI and competition. The filing warns that AI tools may let clients do more work themselves or buy comparable insights elsewhere, which could add pricing pressure and reduce the perceived differentiation of its information and analytics offerings.
  • Client funding and drug pricing. Smaller biotech clients rely on venture funding. The filing also cites the Inflation Reduction Act and a May 2025 executive order on most-favored-nation drug pricing as possible drags on client R&D spending.
  • Currency. About 30% of 2025 revenues were in currencies other than the U.S. dollar, across roughly 60 currencies. Not all currency risk is hedged.

What management is watching

  • Segment change. From January 1, 2026, Contract Sales & Medical Solutions folds into Technology & Analytics Solutions, renamed Commercial Solutions. Real-World Late Phase and certain other Real-World offerings move to Research & Development Solutions. Recast figures start with the Form 10-Q for the three months ended March 31, 2026.
  • Backlog. Research & Development Solutions contracted backlog was $32.7 billion, up from $31.1 billion, with approximately $8.3 billion expected to convert to revenue in the next 12 months. Total remaining performance obligations were approximately $34.2 billion.
  • Restructuring. Actions to consolidate functions and eliminate redundant positions are expected throughout 2026.
  • Spending priorities. The company points to acquisitions, AI-enabled products, business transformation and emerging markets. Data acquisition commitments due in 2026 are $651 million.
  • Liquidity and measures. The company drew $800 million of its $2,000 million revolving credit facility and has $1,769 million of remaining share repurchase authorization. It highlights constant currency growth, which strips out exchange-rate effects, to compare periods.

What the latest 10-Q says

A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 30, 2026, filed October 27, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The quarter in brief

IQVIA's third-quarter revenues were $4,428 million, up 8.0% from the same quarter in 2025, with both segments growing. Income from operations rose to $572 million from $553 million. Costs grew in step with sales, and interest expense and restructuring costs rose. Management also trimmed the Research & Development Solutions backlog (contracted work not yet performed) after refining how it counts inactive trials.

How the business did

  • Revenue: Third-quarter revenues grew 8.0%, and constant currency growth (which strips out exchange-rate effects) was 8.6%. For the first nine months, revenues were $12,947 million, up 8.4%. Commercial Solutions reached $1,789 million, up 6.9%, led by patient solutions. Research & Development Solutions reached $2,639 million, up 8.7%, driven by higher volumes in clinical services and lab testing.
  • Profit: Segment profit was $410 million for Commercial Solutions (against $357 million) and $571 million for Research & Development Solutions (against $522 million). Selling, general and administrative expenses were $569 million against $514 million, mainly higher pay including stock-based compensation. Restructuring costs were $36 million against $20 million. Interest expense was $203 million against $189 million, on higher debt.
  • Cash and capital return: Operating cash flow for nine months was $2,001 million against $1,919 million. The company repurchased 5.5 million shares for $950 million, leaving $2,819 million of repurchase authorization. Cash was $2,249 million.
  • Debt: Total indebtedness was $16,172 million. On September 23, 2026 the company sold $2,000 million of 6.375% senior notes due 2034. It used part of the proceeds to retire notes maturing in October 2026 and to repay revolving credit borrowings.
  • Unusual item: The backlog was $32.6 billion at September 30, 2026, against $34.0 billion at December 31, 2025. The $2.1 billion reduction came from the refined criteria for inactive trials.

What management is watching

  • Management expects about $9.4 billion of the Research & Development Solutions backlog to convert to revenue in the next twelve months. The filing gives no formal full-year targets.
  • Restructuring, meaning consolidating functions and eliminating redundant positions, is expected to continue throughout 2026 and into 2027.
  • Since January 1, 2026 the company reports two segments, Commercial Solutions and Research & Development Solutions, and says it may not achieve the expected benefits of the reorganized structure.
  • Management points to constant currency growth, segment profit and backlog, and says cash, operating cash flow and credit facilities should cover needs for at least the next 12 months. It continues to assess the global minimum tax rules (Pillar Two) for its tax provision.

Follow IQV in Kortex

The Kortex app shows IQV's price, options chain and IV rank, and answers your questions from live market data and SEC filings.

Free to download.

Learn the strategies

More stock briefs

For education only, not financial advice. Options involve risk and are not suitable for every investor.